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The human microbiome consists of ∼3.8 × 1013 symbiotic microorganisms that form
a highly complex and dynamic ecosystem: the gastrointestinal (GI) tract constitutes the
largest repository of the human microbiome by far, and its impact on human neurological
health and disease is becoming increasingly appreciated. Bacteroidetes, the largest
phylum of Gram-negative bacteria in the GI tract microbiome, while generally beneficial
to the host when confined to the GI tract, have potential to secrete a remarkably
complex array of pro-inflammatory neurotoxins that include surface lipopolysaccharides
(LPSs) and toxic proteolytic peptides. The deleterious effects of these bacterial exudates
appear to become more important as GI tract and blood-brain barriers alter or increase
their permeability with aging and disease. For example, presence of the unique LPSs
of the abundant Bacteroidetes species Bacteroides fragilis (BF-LPS) in the serum
represents a major contributing factor to systemic inflammation. BF-LPS is further
recognized by TLR2, TLR4, and/or CD14 microglial cell receptors as are the pro-
inflammatory 42 amino acid amyloid-beta (Aβ42) peptides that characterize Alzheimer’s
disease (AD) brain. Here we provide the first evidence that BF-LPS exposure to
human primary brain cells is an exceptionally potent inducer of the pro-inflammatory
transcription factor NF-kB (p50/p65) complex, a known trigger in the expression of
pathogenic pathways involved in inflammatory neurodegeneration. This ‘Perspectives
communication’ will in addition highlight work from recent studies that advance novel
and emerging concepts on the potential contribution of microbiome-generated factors,
such as BF-LPS, in driving pro-inflammatory degenerative neuropathology in the AD
brain.
Keywords: 42 amino acid amyloid-beta (Aβ42) peptides, Alzheimer’s disease, bacteroidetes, DAMPs and PAMPs,
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THE HUMAN MICROBIOME AND Bacteroides fragilis
Homo sapiens and their complex microbiome, consisting chiefly of bacteria with microbial
eukaryotes, archaea, fungi, protozoa, viruses, and other microorganisms making up the balance,
together compromise the entire metaorganism whose symbiotic associations and host interactions
are critical to human health and disease (Hugon et al., 2015; Seksik and Landman, 2015; Youssef
et al., 2015). There are approximately 52 recognized divisions of bacteria, however, humans, have
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co-evolved with – 2 dominant phyla: Bacteroidetes [about
20% of all gastrointestinal (GI) tract bacteria] and Firmicutes
(about 80%); with Actinobacteria (about 3%), Proteobacteria
(∼1%), and Verrucomicrobia (∼0.1%) making up significantly
smaller fractions. These four major bacterial divisions represent
the ‘bacterial-core’ of the human microbiome (Hakansson and
Molin, 2011; Zhao et al., 2015; Hug et al., 2016; Sender et al.,
2016). About 98% of GI tract microbiota consists of anaerobic
bacteria, and Bacteroidetes species, constituting ∼30% of all GI
tract bacteria are the most abundant Gram-negative bacteria
found in the GI tract outnumbering Escherichia coli abundance
by at least 100 to 1 (Fathi and Wu, 2016; Foster et al., 2016; Hug
et al., 2016; Rogers and Aronoff, 2016; Sampson and Mazmanian,
2016; Sender et al., 2016).
Bacteroidetes species such as Bacteroides fragilis, normal
commensals of the GI tract, are thought to be generally beneficial
to human health via their production of polysaccharides,
volatile fatty acids, cleavage of dietary fibers into digestible
short-chain fatty acids, and other nutrients, however, when
they escape this environment they can cause substantial
inflammatory pathology with significant morbidity and mortality
(Hofer, 2014; Khanna and Tosh, 2014; Fathi and Wu, 2016).
Dietary intake may have a role in regulating the composition
and stoichiometry of the GI tract microbiome; for example
Bacteroidetes species have been observed to proliferate in porcine
models fed high-fat diets deprived of sufficient dietary fiber
(Heinritz et al., 2016). In addition to their lipopolysaccharide
(LPS) generation, B. fragilis endotoxins are a leading cause
of anaerobic bacteremia and sepsis/systemic inflammatory
distress through their generation of the highly pro-inflammatory
zinc metalloprotease metalloproteinase B. fragilis toxin (BFT)
fragilysin (Choi et al., 2016; Fathi and Wu, 2016). BFT has
recently been shown to disrupt epithelial cells of GI tract barriers
via cleavage of the synaptic adhesion zonula adherens protein
E-cadherin (Seong et al., 2015; Choi et al., 2016; Zhan and
Davies, 2016). It is currently not well understood if GI tract
barrier-disrupting proteolytic endotoxins such as BFT are able
to propagate pathogenic actions via the systemic circulation to
further disrupt the blood-brain barrier and transfer LPS, BFT,
and other endotoxins into the cerebrovascular circulation to the
neural cells and synaptic circuitry of the CNS. B. fragilis has been
shown to play a pathological role in neurodevelopment including
autism spectrum disorder (ASD) via circulating metabolites
(Hofer, 2014). It has also recently been reported that along with
BFTs amyloid peptide-dependent changes in synaptic adhesion
affect both the function and integrity of synapses, suggesting that
the observed deficits in synaptic adhesion in Alzheimer’s disease
(AD) play key roles in the progressive disruption of functional
signaling throughout neuronal networks (Lin et al., 2014; Seong
et al., 2015; Leshchyns’ka and Sytnyk, 2016).
INFLAMMATORY SIGNALING IN
ALZHEIMER’S DISEASE (AD)
Multiple and highly interactive aspects of increased inflammatory
signaling is a consistent and recurrent feature of AD and
the major pathological lesions that define AD, including
insoluble Aβ42-enriched peptide deposits, neurofibrillary tangles,
apoptotic, damaged, and dying neurons, and activated microglia
are potent neuropathological stimulants that maintain the
brain in a chronic and self-reinforcing inflammatory state
(Hill and Lukiw, 2015; Calsolaro and Edison, 2016; Minter
et al., 2016; Richards et al., 2016; Varatharaj and Galea, 2016).
These progressive and ultimately fatal pro-inflammatory and
neurodegenerative processes appear to be further stimulated
by aberrant or excessive deregulation of the innate-immune
response, and an increasing focus has been placed on pathological
contributions by the human microbiome including dietary effects
on microbial composition that appear to support pathological
functions (Hill and Lukiw, 2015; Zhao et al., 2015; Foster et al.,
2016). There is a wealth of accumulating evidence (a) that specific
types of microbial LPS and endotoxins (such as BF-LPS and BFT)
from enterotoxigenic microbes specifically impact microglial-
mediated innate-immune responses, phagocytic, and detoxifying
mechanisms and amyloidogenesis characteristic of inflammatory
neurodegeneration (Bhattacharjee and Lukiw, 2013; Hill et al.,
2014; Clark and Vissel, 2015; Hill and Lukiw, 2015; Lim et al.,
2015); and (b) a resurgence of our interest in the importance of
GI tract and blood-brain barrier systems that normally exclude
these microbiome-sourced toxins from the systemic circulation
and CNS but become leaky with age and disease (Montagne
et al., 2015; Choi et al., 2016; Minter et al., 2016; Richards
et al., 2016; Soenen et al., 2016; van de Haar et al., 2016;
Varatharaj and Galea, 2016; Zhan and Davies, 2016; Zhao et al.,
2016).
Interestingly, while secreted LPS, proteolytic endotoxins,
and amyloid monomers are generally soluble as monomers
over time they form into highly insoluble fibrous protein
aggregates that are implicated in the progressive degenerative
neuropathology of several common, age-related disorders of
the human systemic circulation and CNS including systemic
inflammation response syndrome, multiple sclerosis (MS), prion
disease, and AD (Asti and Gioglio, 2014; Clark and Vissel, 2015;
Devier et al., 2015; Richards et al., 2016; Zhao et al., 2016).
At the genetic level, virtually all of this inducible inflammatory
signaling within the CNS involves NF-kB activation and NF-
kB-recognition and binding to target NF-kB DNA sequences
as a prelude to the up-regulation of pro-inflammatory gene
expression pathways, including the up-regulation of discrete
families of pro-inflammatory pathogenic microRNAs that
selectively down-regulate their mRNA targets (Lukiw and Bazan,
1998; Lukiw et al., 2008; Devier et al., 2015; Zhao et al.,
2016).
LIPOPOLYSACCHARIDE (LPS) AND LPS
SIGNALING
Lipopolysaccharides are characteristic components of the outer
leaflet of the outer membrane of Gram-negative bacteria shed
into the extracellular space that play key roles in host–
pathogen interactions of the innate-immune system (Hill and
Lukiw, 2015; Zhao et al., 2015; Jiang et al., 2016; Maldonado
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et al., 2016). While LPSs contain large and hypervariable
polysaccharide/oligosaccharide regions, the relatively conserved
lipid region (lipid A) is the endotoxic and biologically active
moiety that is responsible for septic shock (Jiang et al.,
2016; Maldonado et al., 2016). A “canonical” LPS structure is
represented by that of LPS from E. coli, that contains one of
the most potent neurotoxic lipid A species known, consisting
of a 1,4′-biphosphorylated glucosamine disaccharide bearing six
fatty acids which are unbranched chains 12–14 methyl(ene)
units in length. Other ‘lipid A’ species show variability in the
number, length, and composition of the attached fatty acids,
as well as variability in the degree of phosphorylation and
number and types of substituted phosphate ligands. For instance,
BF-LPS lipid A is penta-acylated and mono-phosphorylated
and contains branched fatty acids 15–17 methyl(ene) units
in length; deviations from the canonical lipid A structure
are known to have a profound impact on the host innate-
immune responses. LPS activates Toll-like receptors (TLRs),
membrane-spanning protein receptors expressed in microglial
cells of the innate immune system which recognize common
damage- or pathogen-associated molecular-patterns (DAMPS,
PAMPs; Gustot et al., 2013; Land, 2015; Maldonado et al.,
2016; Minter et al., 2016; Richards et al., 2016; Varatharaj and
Galea, 2016). TLRs play key roles in host protection from
microbial invasion via the activation of the innate-immune
system by sensing structurally conserved DAMPS or PAMPs
from microbes or microbial exudates that are distinguishable
from, and not innate to, the host organism (Land, 2015; Yu and
Ye, 2015). Interestingly, of the 13 currently characterized TLRs
the microglial TLR2 and TLR4 are activated by amyloid, LPS,
lipoglycans and/or other microbial triggers that subsequently
induce cytokine production, inflammation, phagocytosis and
innate immune defense responses that directly impact the
development of CNS pathology. More specifically, the TLR2
complex can recognize biofilm-associated LPS and amyloids
produced by both Bacteroidetes and Firmicutes (Nishimori et al.,
2012; Bhattacharjee and Lukiw, 2013; Asti and Gioglio, 2014; Hill
and Lukiw, 2015). Interestingly, Aβ42 peptides overproduced in
AD that are associated with microglia-mediated inflammatory
responses have very recently been shown to activate TLR2 and/or
TLR4 (Hill and Lukiw, 2015; Yu and Ye, 2015; Minter et al.,
2016). Of further interest is: (a) that microbial amyloids induce
pro-inflammatory interleukin IL-17A and IL-22, triggers for
NF-kB activation/signaling and cyclooxygenase 2 activation via
direct TLR2 activation (Nishimori et al., 2012); and (b) that
increased levels of both IL-17A and IL-22 are associated with
age-related inflammatory neurodegenerative diseases such as AD
(Zhang et al., 2013; Calsolaro and Edison, 2016; Maldonado
et al., 2016; Richards et al., 2016). Bacterial endotoxin- and
LPS-induced neuro-inflammation has been known for some
FIGURE 1 | Relative induction of NF-kB (p50/p65)-DNA binding in pro-inflammatory factor and lipopolysaccharides (LPS)-treated primary human
neuronal-glial (HNG) co-cultures. (A) HNG cells in primary co-culture for 1.5 weeks; HNG cells were stained with a neuron-specific β-tubulin III (red fluorescence
λmax∼650 nm; anti-βTUBIII antibody, Sigma-Aldrich, St Louis, MO, USA); an antibody against glial fibrillary acidic protein (GFAP; green fluorescence; λmax
∼510 nm; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and DAPI nuclear stain (blue fluorescence; λmax∼470 nm; Thermo Fisher Scientific, Waltham, MA,
USA); 20×; (B) induction of the pro-inflammatory transcription factor NF-kB (p50/p65 activation complex) by various physiologically relevant, pro-inflammatory
factors all at equal dosage (25 nM); NF-kB abundance was measured by NF-kB-DNA binding assay (a measure of NF-kB activation and binding to NF-kB-DNA
recognition sequences) onto a 36 nucleotide end-labeled double stranded DNA fragment containing the canonical human NF-kB (p50/p65) recognition sequence
5′-GGGGACTTTCCC-3′ as previously described (Lukiw and Bazan, 1998; Lukiw et al., 2008; Devier et al., 2015; Clement et al., 2016); a scrambled control
nucleotide containing no such NF-kB recognition sequence showed NF-kB-DNA binding activity (data not shown); (C) data from gel bands in panel (B) quantified in
bar graph format; note robust induction of the NF-kB (p50/p65 complex) by Escherichia coli lipopolysaccharide (EC-LPS; LPS from Escherichia coli 0111:B4; Sigma
L3012, St Louis, MO, USA) or B. fragilis lipopolysaccharide (BF-LPS; prepared by methods previously published; Eidhin and Mouton, 1993) that was ∼45- to
∼55-fold higher than that of the control human serum albumen (HSA) protein, and was fivefold to sevenfold higher than the combination of the pro-inflammatory
Aβ42 peptide and IL-1β together (at 25 nM each); complex mixtures of microbiome bacterial LPS on NF-kB induction might be expected to be additive or
synergistic; HSA = (control) human serum albumen; CFH = complement factor H; TNFα = tumor necrosis factor alpha (cachectin); IL-1β = interleukin 1-beta; Aβ40,
Aβ42 = amyloid beta peptide, 40 and 42 amino acids in length; EC-LPS, BF-LPS = E. coli, Bacteroides fragilis lipopolysaccharide; error bars represent one
standard error of the mean; N = 4; ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001, ANOVA.
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time to be important in driving the generation of Aβ42 (Lee
et al., 2008; Asti and Gioglio, 2014; Hill and Lukiw, 2015;
Zhao et al., 2015). In addition to TLR2 and TLR4 at least
one additional microglial transmembrane LPS receptor CD14
mediates phagocytosis of both bacterial components and Aβ42
peptides, hence expanding roles for microglia and microglial
LPS receptors in the pathophysiology of AD (Lee et al., 2008;
Halmer et al., 2015; Jiang et al., 2016). Of further interest
is that gram negative bacterial exudates such as BF-LPS are
hypervariable in composition, and different Bacteroidetes species
appear to generate unique temporal patterns of LPS that exhibit
rapid adaptive changes – these include the modulation of
LPS synthesis and structure and alterations in DAMP/PAMP
recognition features as strategies for host immune system evasion
(Land, 2015; Maldonado et al., 2016; Richards et al., 2016).
CONCLUDING REMARKS
We hope that this ‘Perspectives’ article has adequately
highlighted some recent findings on microbial-derived LPS
and proteolytic endotoxins and has engendered interest in
the potential contribution of these neurotoxic and pro-
inflammatory microbial exudates to amyloidogenesis and
age-related inflammatory neurodegeneration. Taken together,
these current observations advance seven key areas in our
understanding of the role of the microbiome in progressive,
age-related inflammatory neurodegeneration: (a) that relatively
low, nanomolar amounts of bacterial LPS are extremely potent
inducers of the pro-inflammatory transcription factor NF-kB
(p50/p65 complex) in human primary human neuronal-glial
(HNG) co-cultures of brain cells (Figure 1); (b) that different LPS
preparations from different bacterial species appear to exhibit
slightly different trends in the induction of an inflammatory
response, as quantified by the extent (mean values) of NF-kB
activation and DNA-binding (Figure 1); (c) that the proliferation
of microbial species such as the BF-LPS and BFT generating
Bacteroidetes may be regulated by diet, environment, and lifestyle
factors such as dietary fiber intake can impact neurological
health, CNS inflammation, and degenerative disease (Hofer,
2014; Khanna and Tosh, 2014; Zhan and Davies, 2016); (d) that
LPS transit across compromised GI tract and blood-brain barriers
underscore the critical roles of cellular adhesion structures in
allowing passage of noxious molecules from the GI tract into the
systemic circulation and CNS (Montagne et al., 2015; Soenen
et al., 2016; van de Haar et al., 2016); (e) that biophysical,
gastrointestinal, and neurobiological barriers which may become
more ‘leaky’ with aging again underscore the important role of
tight junctions in moderating systemic and CNS inflammation
and immune-mediated inflammatory disease (Hill and Lukiw,
2015; Varatharaj and Galea, 2016); (f) that DAMPS and/or
PAMPs common to both LPS, endotoxins, and/or amyloid
may trigger TRL2, TRL4 and/or CD14 microglial receptors
to propagate and sustain inducible AD-relevant inflammatory
responses within the CNS (Land, 2015; Zhao and Lukiw, 2015;
Varatharaj and Galea, 2016); and (g) that LPS abundance,
speciation and complexity in the CSF and/or blood serum may be
useful diagnostically for the onset of mild cognitive impairment
(MCI), the clinical precursor for the development of AD. Clearly,
more research into the intriguing realm of human microbiome-
host interaction is warranted, and the study of the complex
interactions between each biological niche is certain to shed
new light on the still evolving concepts and mechanisms of
microbiome interplay and control in human neurological health
and disease.
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